

VPA10996/149/001

OVIVAC P PLUS

Variation	Summary	Date
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	29/01/25
Vet - F.I.b.2 z)	VRA-S - Vet - F.I.b.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.I.b.2 z) Quality Changes - Active Substance - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	20/11/24
Vet - F.II.d.2 z)	VRA-S - Vet - F.II.d.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.d.2 z) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	20/11/24
Vet - B47 b)	VNRA - Vet - B47 b) - b) Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - B47 b) Changes to the quality part of the dossier: Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State: — change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State	20/10/23
Vet - F.II.d.2 b)	VRA-S - Vet - F.II.d.2 b) - b) Other changes to a test procedure (including replacement or addition) - F.II.d.2 b) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	01/08/23
Vet - F.II.b.2 a) 1.	VRA-S - Vet - F.II.b.2 a) 1. - a) Replacement or addition of a site where batch control/testing takes place 1. Replacement or addition of a site where batch control/testing takes place for a	17/04/23

	biological/immunological veterinary medicinal product and any of the test methods performed at the site is a biological/immunological method - F.II.b.2 a) 1. Quality Changes - Finished Product -Manufacture - Change to importer, batch release arrangements and quality control testing of the finished product - Replacement or addition of a site where batch control/testing takes place - Replacement or addition of a site where batch control/testing takes place for a biological/immunological veterinary medicinal product and any of the test methods performed	
Vet - F.II.d.2 b)	VRA-S - Vet - F.II.d.2 b) - b) Other changes to a test procedure (including replacement or addition) - F.II.d.2 b) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	17/04/23
Vet - F.II.d.2 b)	VRA-R - Vet - F.II.d.2 b) - b) Other changes to a test procedure (including replacement or addition) - F.II.d.2 b) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	17/04/23
Vet - F.I.a.2 b)	VRA-S - Vet - F.I.a.2 b) - b) The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - F.I.a.2 b) Quality Changes - Active Substance - Manufacture - Changes in the manufacturing process of the active substance - The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol	29/03/23
Vet - F.I.b.2 a)	VRA-S - Vet - F.I.b.2 a) - a) Substantial change to or replacement of a biological/immunological/immunochemical test - F.I.b.2 a) Quality Changes - Active Substance - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Substantial change to or replacement of a biological/immunological/immunochemical test	29/03/23
Vet - F.II.d.2 b)	VRA-S - Vet - F.II.d.2 b) - b) Other changes to a test procedure (including replacement or addition) - F.II.d.2 b) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	04/10/22
B.I.b.2.d	II - B.I.b.2.d - d) Substantial change to or replacement of a	17/06/22

	biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - B.I.b.2.d - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance	
B.I.b.2.d	II - B.I.b.2.d - d) Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - B.I.b.2.d - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance	17/06/22
B.I.b.2.d	II - B.I.b.2.d - d) Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - B.I.b.2.d - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance	17/06/22
B.I.a.2.c	II - B.I.a.2.c - c) The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - B.I.a.2.c - QUALITY CHANGES - ACTIVE SUBSTANCE - Manufacture - Changes in the manufacturing process of the active substance - The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol	16/02/22
B.I.a.2.c	II - B.I.a.2.c - c) The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a	16/02/22

	significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - B.I.a.2.c - QUALITY CHANGES - ACTIVE SUBSTANCE - Manufacture - Changes in the manufacturing process of the active substance - The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol	
B.I.a.2.c	II - B.I.a.2.c - c) The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - B.I.a.2.c - QUALITY CHANGES - ACTIVE SUBSTANCE - Manufacture - Changes in the manufacturing process of the active substance - The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol	16/02/22
B.I.a.2.c	II - B.I.a.2.c - c) The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - B.I.a.2.c - QUALITY CHANGES - ACTIVE SUBSTANCE - Manufacture - Changes in the manufacturing process of the active substance - The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol	16/02/22
B.I.a.2.c	II - B.I.a.2.c - c) The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - B.I.a.2.c - QUALITY CHANGES - ACTIVE SUBSTANCE - Manufacture - Changes in the manufacturing process of the active substance - The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a	16/02/22

	significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol	
B.I.a.2.c	II - B.I.a.2.c - c) The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - B.I.a.2.c - QUALITY CHANGES - ACTIVE SUBSTANCE - Manufacture - Changes in the manufacturing process of the active substance - The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol	16/02/22
B.I.b.2.e	IB - B.I.b.2.e - e) Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - B.I.b.2.e - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate	16/02/22